TNFSF4 and pancreatic adenocarcinoma: Additional strategies exploit EVs engineered to express OX40 ligand (OX40L), converting M2 macrophages to M1, and enhancing macrophage-mediated immunity in pancreatic adenocarcinoma models [267].